30 closest matches · ranked by relevance
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Influenza
Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45
Influenza A · Influenza B
Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 84.03; 40.48; 306.51; 159.02 Titer
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Influenza A H3N2 · Influenza A H1N1
Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants
Influenza
Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 136.2; 114.1; 117.4 Hours — p=0.377
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Influenza
Primary: Geometric Mean Titer (GMT) of Serum Haemagglutination-inhibition (HI) Antibodies — 52.4; 101.4; 80.5; 218.0 Titer
Influenza
Primary: Number of Subjects With at Least One Influenza-like-infection (ILI) Episode — 133; 243; 376; 125 Participants
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 15.5; 11.4; 139.7; 55.8 titer
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 13.6; 11.6; 165.5; 68.2 titer
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Influenza, Human · Immune Response
Primary: Number of Participants With Seroconversion Response In 2019 — 5; 33; 11; 44 Participants — p=<0.001
Influenza
Primary: Change in Inflammatory Markers From Time Zero to 72 Hours — 2.4; 3.46; 0.91; 0.57 pg/ml — p=0.611
Influenza Prophylaxis
Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres
Influenza Vaccines
Primary: Hemagglutination Inhibition (HI) Antibody Titers — 19.5; 13.9; 116.0; 47.1 titer
Influenza
Primary: Hemagglutination Inhibition (HI) Antibody Titer — 10.2; 8.7; 314.1; 89.4 titer
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Influenza
Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 61.0; 65.7; 337.4; 207.5 Titer
Influenza
Primary: Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains — 10.4; 10.6; 10.9; 106.1 titre
Human Influenza
Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres
Influenza
Primary: Influenza Immunization: Pediatric — 43.6; 39.9 % participant vaccinated with influenza